Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC) (ECLIPSE)

Objectives: Novel iniparib is not a typical PARP inhibitor; its exact mechanism is still being elucidated but it has shown anticancer activity. The primary outcome measure is overall survival.

Key entry or exclusion criteria: Stage IV squamous cell lung cancer must be newly diagnosed; at least 12 months must have passed if patient had adjuvant therapy for early-stage lung cancer.

Locations: 148 sites.

Goal: 780 patients.

Study sponsor: Sanofi-Aventis in collaboration with BiPar Sciences

Link for more information: https://clinicaltrials.gov/ct2/show/NCT01082549

NIH clinical trial identifier: NCT01082549